Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials

被引:29
作者
Weinfurt, KP
DePuy, V
Castel, LD
Sulmasy, DP
Schulman, KA
Meropol, NJ
机构
[1] Duke Univ, Ctr Clin & Genet Econ, Duke Clin Res Inst, Med Ctr, Durham, NC 27715 USA
[2] St Vincent Catholic Med Ctr, John J Conley Dept Eth, St Vincents Manhattan, New York, NY USA
[3] New York Med Coll, Bioeth Inst, Valhalla, NY 10595 USA
[4] Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19111 USA
[5] Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA
关键词
Phase I clinical trials; communication; decision making; informed consent; neoplasms; patient participation; perception; physician-patient relations; truth disclosure;
D O I
10.1002/cncr.20730
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. There is concern that patients with poor numeracy may have difficulty understanding the information necessary to make informed treatment decisions. The authors sought to characterize a special form of numeracy among patients with advanced cancer who were offered participation in Phase I oncology clinical trials. METHODS. Surveys were administered to 328 cancer patients who were considering Phase I trials. Their frequency-type numeracy was assessed using a multiple-choice question involving a hypothetical scenario in which a physician stated that an experimental treatment would control cancer in "40% of cases like yours." In univariate and multivariable analyses, patient characteristics that were associated with better numeracy were identified. RESULTS. The correct frequency-type interpretation was selected by 72% of respondents. Fourteen percent of respondents incorrectly selected a belief-type answer, "The doctor is 40% confident that the treatment will control my cancer." In a multivariable model, patients who answered incorrectly tended to have less formal education and less experience with experimental therapies. CONCLUSIONS. Because the Misunderstandings some patients demonstrated may influence their treatment decision making adversely, it is critical to identify such patients and to give them special consideration when communicating information about potential risks and benefits of treatment. (C) 2004 American Cancer Society.
引用
收藏
页码:140 / 147
页数:8
相关论文
共 35 条
  • [1] Ethics of phase 1 oncology studies - Reexamining the arguments and data
    Agrawal, M
    Emanuel, EJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (08): : 1075 - 1082
  • [2] ANNAS GJ, 1994, NEW ENGL J MED, V331, P811
  • [3] [Anonymous], 2004, THEORY GAMES EC BEHA
  • [4] THE THERAPEUTIC MISCONCEPTION - INFORMED CONSENT IN PSYCHIATRIC RESEARCH
    APPELBAUM, PS
    ROTH, LH
    LIDZ, C
    [J]. INTERNATIONAL JOURNAL OF LAW AND PSYCHIATRY, 1982, 5 (3-4) : 319 - 329
  • [5] FALSE HOPES AND BEST DATA - CONSENT TO RESEARCH AND THE THERAPEUTIC MISCONCEPTION
    APPELBAUM, PS
    ROTH, LH
    LIDZ, CW
    BENSON, P
    WINSLADE, W
    [J]. HASTINGS CENTER REPORT, 1987, 17 (02) : 20 - 24
  • [6] INFORMED CONSENT - HOW MUCH DOES THE PATIENT UNDERSTAND
    BERGLER, JH
    PENNINGTON, AC
    METCALFE, M
    FREIS, ED
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 27 (04) : 435 - 440
  • [7] Informed consent for cancer screening with prostate-specific antigen: How well are men getting the message?
    Chan, ECY
    Vernon, SW
    O'Donnell, FT
    Ahn, C
    Greisinger, A
    Aga, DW
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 2003, 93 (05) : 779 - 785
  • [8] What should men know about prostate-specific antigen screening before giving informed consent?
    Chan, ECY
    Sulmasy, DP
    [J]. AMERICAN JOURNAL OF MEDICINE, 1998, 105 (04) : 266 - 274
  • [9] Adjuvant chemotherapy for breast cancer: How presentation of recurrence risk influences decision-making
    Chao, C
    Studts, JL
    Abell, T
    Hadley, T
    Roetzer, L
    Dineen, S
    Lorenz, D
    YoussefAgha, A
    McMasters, KM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 4299 - 4305
  • [10] Impact of quality of life on patient expectations regarding phase I clinical trials
    Cheng, JD
    Hitt, J
    Koczwara, B
    Schulman, KA
    Burnett, CB
    Gaskin, DJ
    Rowland, JH
    Meropol, NJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) : 421 - 428